Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAROL real-world darolutamide study in non-metastatic castration-resistant prostate cancer
ChiCTR2200057479Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darolutamide in castration-resistant prostate cancer (CRPC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Safety. Started Mar 2022; status: recruiting.
02
Drugs
darolutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ChiCTR2200057479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057479.